Parallel Bio Secures $21 Million in Series A to Advance Human-First Drug Discovery
CAMBRIDGE, Mass., June 12, 2025--(BUSINESS WIRE)--Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round attracted prominent leaders in AI and biotech, including new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.
The company also revealed that 8 pharmaceutical partners, including three Fortune 500 companies, are testing more than 50 drugs and immunotherapies using its organoid-based immune system platform—including Centivax, which completed the first preclinical testing on the platform for its universal flu vaccine candidate.
"With these milestones, we are closer to making human-first drug discovery the new industry standard," said Robert DiFazio, CEO and co-founder at Parallel Bio. "For too long, the reliance on lab mice to model human biology has come at a high cost: 95% of drugs fail in human trials even after succeeding in animal studies. We're turning that on its head by using organoids and AI to discover drugs in true-to-life human models from the start."
Parallel Bio will use the new capital to scale the AI and automation capabilities of its organoid-based immune system platform, expand its team of scientists and engineers, and support growing pharmaceutical partnerships. To date, Parallel Bio has raised a total of nearly $30 million, including this Series A and previous seed rounds.
Parallel Bio's platform combines lymph-node organoids with AI and robotics to replicate the human immune system at scale across diverse populations. Organoids are 3D, self-assembling models of human biology. These miniature organs mimic an organ's structure and function and the body's response to disease or treatment, as if the organoids were individual patients.
AIX Ventures partner Krish Ramadurai, who joined the company's board of directors as part of the round, commented: "Parallel Bio is redefining drug development by turning the conventional model upside down—transforming today's 95% failure rate into a pathway for 95% success. Their groundbreaking human-first platform unlocks biological insights previously impossible to capture, accelerating the development of effective treatments that reach patients faster while generating de novo biological data to power the next generation of AI-driven therapeutics. We're thrilled to partner with the Parallel Bio team in setting a new gold standard for the future of medicine."
Since launching Clinical Trial in a Dish last year, Parallel Bio has seen growing demand from pharmaceutical companies. This first commercial application accurately predicts the safest and most effective drug candidates for human trials.
"Starting with human models enables new drugs to reach the market at a pace never possible before," said Juliana Hilliard, Parallel Bio co-founder and chief scientific officer. "We aim to slash $2 billion and 9 years from each drug candidate in development by predicting success at the earliest stages of discovery."
Centivax Validates Broad Immune Response in Organoid Trial
Parallel Bio partnered with Centivax, a universal immunity biotechnology company, to generate human-first data to validate Centivax's first program: a universal flu vaccine called Centi-Flu that is now in manufacturing for human clinical trials, with the first patient expected to be dosed early next year.
"Parallel Bio enables us to derisk the single biggest source of failure in vaccine development: making sure the vaccines work in humans before the human trials have even begun," said Jacob Glanville, president and CEO at Centivax. "Even though we have validated our pan-influenza responses in mice, rats, pigs, and ferrets, ultimately we are making a universal vaccine for humans. Parallel Bio's platform is transformative by allowing us to directly validate our results in immune organoids derived from adult humans."
The organoid study revealed the power of the Centi-Flu technology: by effectively targeting common features of the virus shared by many different influenza strains, Centi-Flu even produces strong immune responses against strains not included in the vaccine. Human immune organoids were "vaccinated" with Centi-Flu, leading to the production of B cells capable of reacting to a wide variety of flu strains. The immune organoids were derived from patients with prior flu exposure, proving that Centi-Flu could trigger broad humoral responses in flu-exposed individuals.
The organoid model also showed activation of CD4+ and CD8+ T cells, which are important for fighting infections, suggesting that Centi-Flu helps stimulate both antibody production and T cell immunity. This combination is particularly valuable for protecting against severe flu, including hospitalization and death.
About Parallel Bio
Parallel Bio is pioneering human-first drug discovery by combining organoids and AI to create true-to-life models of human biology. The company developed the first platform that replicates the human immune system across diverse populations, predicting drug success and identifying disease targets with accuracy and speed far beyond the limits of traditional animal models. Pharmaceutical partners, including three Fortune 500 companies, are using its Clinical Trial in a Dish to test the safety and efficacy of immunotherapies. Based in Cambridge, Mass., Parallel Bio was founded in 2021 by two scientists behind the world's first scalable human immune organoid.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612697548/en/
Contacts
Media contactMatt Hickspress@parallel.bio
Business contactRobert DiFaziobd@parallel.bio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Trump may want lower interest rates for consumers, but it sure is convenient for the national debt he's creating, too
EXCLUSIVE: Donald Trump has escalated attacks on Jerome Powell, blaming high rates for freezing the housing market and urging the Fed to deliver cuts. While Trump frames the issue as consumer pain, Wharton's Joao Gomes told Fortune that cheaper borrowing would also ease interest payments on the government's $37 trillion debt burden—likely a central motivation. Trump's argument for lowering the base interest rate has been clear. Consumers, he says, are suffering financially because Jerome Powell and the Fed refuse to make borrowing cheaper. It's true the housing market has ground to a halt. And at some point, a lower base rate could improve the mortgage offers made to would-be buyers and kickstart activity in the sector. 'Could somebody please inform Jerome 'Too Late' Powell that he is hurting the housing industry, very badly?' the president wrote on Truth Social this week. 'People can't get a mortgage because of him. There is no Inflation, and every sign is pointing to a major Rate Cut. 'Too Late' is a disaster!' The pressure is likely to increase as the weeks roll on, with the Fed's next base rate meeting scheduled to happen in September—and possible hints to come at this week's Jackson Hole Symposium. Likewise, in July, he wrote: 'Housing in our country is lagging because Jerome 'Too Late' Powell refuses to lower interest rates. Families are being hurt because interest rates are too high, and even our country is having to pay a higher rate than it should be because of 'Too Late.'' While Trump's pressure on Powell hasn't been popular with Wall Street, pitching the battle on behalf of consumers is more politically palatable. While Trump leads with the benefit to consumers, economists are focused on Trump's point that the country is also paying more because of Powell's refusal to capitulate to his demands. This is what may be at the heart of the White House's crusade against the current base rate, experts believe, because if the Federal Open Market Committee (FOMC) made borrowing cheaper for everyone, that would include the government. The White House will be well aware of this fact, particularly in an environment where fiscally conservative Republicans will be shuddering at Uncle Sam's $37 trillion (and growing) national debt. Of course, Trump's motivation can be twofold: He can want to foster economic activity, and conveniently bring down his own overheads as well. 'It's both,' Professor Joao Gomes, of the Wharton Business School at the University of Pennsylvania, told Fortune in an exclusive interview. 'I don't know how to weigh those two … but the latter one is incredibly important. I think they're very aware of this. The budget picture would look a lot better if interest rates were 2.5%, 2%, 1%—it would look very, very different.' In 2024, the average rate of interest paid on U.S. borrowing was 3.32%. As of last month, it cost $1.013 trillion to maintain the borrowing, approximately 17% of federal spending for the fiscal year. According to Treasury data seen by Fortune, the accrued interest expense on Treasury notes in July alone was $38.1 billion. Add to that $13.9 billion in interest on Treasury bonds, $2.85 billion on Treasury Floating Rate Notes (FRN) and a total of $6.1 billion across Treasury Inflation-Protected Securities (TIPS) assets. The bill is alarming: The total comes to $60.95 billion for the month. Professor Gomes said bringing down those rates is 'incredibly important': 'It might be more important than the impact it would have on growth.' 'The Trump administration respects the independence of the Federal Reserve to set monetary policy and achieve its dual mandate of keeping inflation and unemployment low,' White House spokesman Kush Desai told Fortune. 'The Fed's own stated objective, however, is to set policy based on what the data show, and the data clearly show that the president's policies have swiftly tamed Joe Biden's inflation crisis. 'The president has made his view clear that it's high time for the Fed to respond to this objective fact by cutting rates, delivering needed interest rate relief to American families and supporting employment and economic growth.' The mortgage question President Trump's implication that a lower base rate would kickstart the housing market isn't a given, Columbia University's Professor Yiming Ma told Fortune, but it could ease some tension for 'locked-in' homeowners. Mortgage rates are partly based on the country's base rate, but over a much longer period of time than the Fed's month-to-month alterations. This means a 0.25bps reduction is unlikely to make a significant difference, Professor Ma said. However, lenders may be looking at a potential cut as a sign of a regime change in monetary policy, signaling that future rates could continue to lower, meaningfully impacting the rates lenders can offer. Mortgage offers take into consideration far more than the Fed, Professor Ma explained: 'Banks will charge a premium, and that premium depends a lot on: How they think the economy is going, what is the likelihood of default, how bad is [the applicant's] funding condition? That all is going to depend on a range of other things within the real economy. The connection between borrowing costs and the short-term interest rate is in theory there, but in practice it depends on so many things.' 'I think in particular the environment we're in right now is one of pretty high uncertainty and even if you get a rate cut … there's still a long way to go until the market will think that we're going to have—for the longer term—lower Interest on accessories or policy rates, and there's going to be a long way to go for people to think the economy is stable enough so that the premium on top of that rate is not going to go higher.' Indeed, when the Fed cut rates last September by 50bps, the average 30-year mortgage rate actually increased per the St Louis Federal Reserve. 'It seems that in this environment that the mortgage rates can zig even when the Fed zags,' Bankrate analyst Jeff Ostrowski told Fortune. 'There's not a clear connection between the Federal Reserve's benchmark rate and mortgage rates.' That being said, a lower base rate may signal to consumers that a lower rate environment is on the way. This, Ostrowski added, could relieve some of the lock-in effect where homeowners don't want to move houses because their longer-term fixed mortgages are set at a rate offered in a previous period of lower interest. To see rates coming down could foster activity and encourage people to start looking at the market. Would consumers benefit or not? As well as releasing some tension in the housing market, there are some clear upsides for certain demographics when it comes to lower rates, added Professor Ma. There would be some 'immediate relief' for people living 'paycheck to paycheck' and relying on credit cards if rates lowered lightly (and especially if they continued to do so) the economist added. According to a study from the St Louis Fed, approximately 27% of people in the bottom 10th percentile have a credit card and 40% of those in the second-to-bottom. In the third percentile, approximately 50% of people had credit cards they needed to pay off, representing a significant portion of the population. But consumers aren't necessarily savers or spenders: Many will benefit from a lower rate on the credit card side, but suffer on their savings side. The Fed reported this year that 59% of people had savings accounts and benefitted from returns at the higher rate. 'Financial institutions are actually very fast to pass on rate cuts to savings,' observed Professor Ma, with Ostrowski echoing: 'I've got a high yield savings account and it's like almost the second the Fed moves I get a notice saying 'your rate just changed,' so it seems like the variable rates will move pretty quickly.' The net impact on consumers is a 'wash' added Ostrowski: 'I get the sense that Americans have shifted so much into storing what wealth they have in the stock market that … it doesn't seem like we hear the same outcry from retirees when rates go down.' 'It's hard to say that there's a real winner or loser because most Americans are consumers and investors, they're spenders and savers,' he added. Why would the government benefit? If the cost of borrowing is cheaper for everyone that doesn't just mean businesses and consumers, it means the government too. Typically, when interest rates are lower the same goes for Treasury yields (government debt and the interest it pays to lenders to service the debt). That hasn't always been the case, over the past year for example yields climbed when the base rate lowered. This was due to a range of factors, wrote JP Morgan, including growth, economic uncertainty and questions over whether the September 2024 cut would spell a change in the tide of monetary policy (spoiler alert: it wasn't). But generally, lower interest rates benefit the government's bottom line because it can issue new debt at a lower premium to maintain the loan. While it's hard to assign a 'weight' to whether Trump's motivation is for voters or his administration, Professor Ma said 'both can be true'. A lower base rate eases 'borrowing for consumers, it's going to ease pressure for companies to borrow, which will stimulate businesses and some of that will be evident in the stock market. These are all important economic indicators for any country—that's definitely true. 'It's also true that consumers and businesses are not the only ones to borrow … The U.S. government borrows a lot right now, and certainly the interest expense on the U.S. Treasury is going to be affected by by the interest rate.' The expert also pointed out that the trickle-through of cheaper borrowing for the government may not be across the board: 'We have Treasury bills that mature within the year, or three months, six months, 12-month horizons. We also have very long-term debts and so cutting interest rates in the overnight maturity is not going to directly pass through necessarily to the very long end.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Exclusive: Crypto startup Legion raises $5 million to bring back ICOs—without the scams
The ICO, or initial coin offering, era was notorious. A decade ago, crypto founders raised millions and even billions from small-time traders by selling cryptocurrencies tied to new projects. Many raises, like the one for Ethereum in 2014, were in good faith. Others were outright scams. Regulators cracked down on the practice, and ICOs soon became another chapter in crypto history. Now, the practice appears to be making a comeback, and the crypto startup Legion hopes to create the go-to platform where companies can—responsibly—sell tokens to small-time traders, say cofounders Fabrizio Giabardo and Matt O'Connor. 'Just think IPO-type rigor, IPO-type access, mixing in with, again, crypto rails,' Giabardo told Fortune. On Wednesday, the pair announced that Legion had raised $5 million in a seed round led by VanEck and Brevan Howard Digital. The crypto exchange Kraken as well as the venture arms of the crypto exchanges Coinbase and also participated in the raise, among other investors. Giabardo and O'Connor declined to disclose their startup's valuation. The round was for equity and token warrants, or promised allocations of a yet-to-be-launched cryptocurrency, they said. ICO boomerang Legion's capital injection comes as ICOs are back in vogue in crypto. In June, the stablecoin project Plasma raised $500 million in five minutes through a public token sale. In July, a memecoin factory that's become one of the most profitable projects in crypto, raised $600 million in 12 minutes. And Cobie, a pseudonymous crypto influencer and investor, has launched his own ICO platform called Sonar. The return of the ICO follows a regulatory thaw in Washington, D.C. President Donald Trump's administration has signaled a friendlier approach to crypto than that of former President Joe Biden. Crypto companies, who once were fleeing the U.S. amid a flurry of lawsuits from the Securities and Exchange Commission, are now returning. And some feel more emboldened to try out ICOs as a means to raise funds. But Giabardo and O'Connor believe their platform will help prevent the outright scams that were common a decade ago—when founders would raise millions off the back of a jargon-filled white paper and then disappear in so-called 'rug pulls.' Both founders are crypto veterans. Giabardo, who had stints as a geologist and then consultant, started exploring crypto in 2020 and eventually began working with the crypto analytics platform Delphi Digital. O'Connor comes from traditional finance, where he worked at the asset manager Bridgewater Associates before he found his way to working on Stacks in 2022, a blockchain built on top of Bitcoin. The two eventually crossed paths and decided to work together to bring back ICOs. Their platform is built to comply with recently released regulatory framework in the European Union for early token launches, they said. The statutes require projects to release a 'white paper' that requires issuers to detail, for example, risks involved with the offering and update their white papers anytime there are material changes to the projects. The two cofounders have also met with the SEC to discuss what disclosures the agency should require for public sales, said O'Connor. 'Give people honest, truthful, succinct disclosures that they can fully understand, do some kind of checking that validates that, yes, they do truly understand these things,' he added. 'And then, it's up to them to take the risks realistically.' This story was originally featured on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Snappt and CLEAR Partner to Deliver Best-in-Class Identity Verification for Multifamily Housing
Strategic integration brings trusted identity verification to Snappt's AI-powered Applicant Trust Platform LOS ANGELES, August 20, 2025--(BUSINESS WIRE)--Snappt, the leading platform for applicant trust in multifamily housing, today announced a strategic partnership with CLEAR, the secure identity company. Through this collaboration, Snappt integrated CLEAR's identity platform, CLEAR1, to enable property managers to streamline applicant verification, reduce fraud at scale, and minimize manual effort. The integration brings together Snappt's 99.8% accurate document fraud detection with CLEAR's identity verification technology to strengthen applicant screening. This combined approach is designed to help property managers address the industry's average fraud rate of 6.5%, according to Snappt's mid-year fraud report, while maintaining a streamlined experience for applicants. "This partnership represents a significant evolution in how our industry approaches applicant verification," said James Hyde, CEO of Snappt. "By integrating CLEAR's trusted technology into our Applicant Trust Platform, we can deliver unparalleled security and user experience to property managers and applicants alike." This integration expands Snappt's growing ecosystem, giving property managers more ways to verify identities without sacrificing speed, simplicity, or security. By embedding CLEAR1, Snappt strengthens its end-to-end fraud prevention toolkit while maintaining operational efficiency. The joint solution is available to all Snappt customers, with seamless onboarding supported by Snappt's account teams. For more information, visit and About Snappt Snappt is the Applicant Trust Platform that helps multifamily property managers prevent fraud, verify income and identity, and build trusted communities at scale. Since its founding in 2019, the company has established itself as the industry leader in AI-powered fraud detection, analyzing more than 14 million documents with 99.8% accuracy. Their platform extends beyond document review, providing comprehensive verification of income, rent, payroll, and identity to ensure property managers can make leasing decisions with confidence. Snappt is also the only provider with a dedicated Fraud Forensics team, enabling customers to stay ahead of increasingly sophisticated fraud tactics. View source version on Contacts Media Contact:Walker Sandssnappt@
